Skip to main content

HTLV-1-infected HIS Rag2-/-γc-/- mice, a suitable model for in vivo investigating the effects of drugs in ATL treatment?

Adult T cell Leukemia, an aggressive T-cell malignancy linked to HTLV-1 infection, is resistant to chemotherapy. Recently, promising results were obtained with the combination of arsenic trioxide, interferon alpha and zidovudine. However, the cellular and molecular mechanisms of their anti-leukemia activity remain to be investigated. To that aim, we have relied on HIS (Human Immune System) Rag2-/-γc-/- mice. We have indeed observed that when infected with HTLV-1, these mice displayed, five months later, an elevated number of human Tax-expressing T cells in the thymus, the spleen and the mesenteric lymph nodes. Some of them also developed T lymphoproliferative diseases.

To determine the effects of these three drugs on the apparition of these pathological features, Rag2-/-γc-/- mice were infected with HTLV-1 and, 16 weeks after infection, daily treated with the drugs for one week and sacrificed. Untreated HIS mice infected with HTLV-1 were used as control. Treatment resulted in a significant decrease in the spleen weight as compared to untreated controls. Interestingly, we also noted a decrease of the proviral load in thymocytes as well as a drop in the number of mature activated T cells in the spleen and in lymph nodes. These data clearly indicate that the HIS mouse model provides us with the opportunity not only for the pre-clinical evaluation of therapeutic approaches against the leukemogenic process associated with HTLV-1 infection, but also for unraveling the corresponding mechanisms.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Madeleine Duc Dodon.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Villaudy, J., Cachat, A., Alais, S. et al. HTLV-1-infected HIS Rag2-/-γc-/- mice, a suitable model for in vivo investigating the effects of drugs in ATL treatment?. Retrovirology 8, A11 (2011). https://doi.org/10.1186/1742-4690-8-S1-A11

Download citation

Keywords

  • Arsenic
  • Interferon
  • Zidovudine
  • Mesenteric Lymph Node
  • Human Immune